A. Hutchaleelaha, Mira P Patel, C. Washington
Mar 31, 2019
Citations
5
Influential Citations
50
Citations
Quality indicators
Journal
British Journal of Clinical Pharmacology
Abstract
Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb‐oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once‐daily oral drug to treat sickle cell disease (SCD). This first‐in‐human study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of voxelotor in healthy volunteers and SCD patients.